1. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. https://www.who.int/hepatitis/publications/global-hepatitisreport2017/en/ Accessed August 13, 2018.
2. Liu J, Zhang SK, Wang QM, Shen HP, Zhang M, Zhang YP, Yan DH, Liu M: Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study. Lancet Infectious Diseases 2016, 16(1):80-86.
3. Bertoletti A, Gehring AJ: The immune response during hepatitis B virus infection. The Journal of general virology 2006, 87(Pt 6):1439-1449.
4. Chisari FV, Isogawa M, Wieland SF: Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010, 58(4):258-266.
5. Samuel CE: Antiviral actions of interferons. Clin Microbiol Rev 2001, 14(4):778-809.
6. Getahun A, Cambier JC: Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin Fc receptor signaling. Immunological Reviews 2015, 268(1):66-73.
7. Esposito-Farese ME, Sautes C, de la Salle H, Latour S, Bieber T, de la Salle C, Ohlmann P, Fridman WH, Cazenave JP, Teillaud JL: Membrane and soluble Fc gamma RII/III modulate the antigen-presenting capacity of murine dendritic epidermal Langerhans cells for IgG-complexed antigens. J Immunol 1995, 155(4):1725-1736.
8. Jessica C. Anania AMC, Bruce D. Wines ,: The Human FcγRII (CD32) Family of Leukocyte FcR in Health and Disease. Frontiers in Immunology 2019, 10.
9. Espeli M, Smith KGC, Clatworthy MR: Fc gamma RIIB and autoimmunity. Immunological Reviews 2016, 269(1):194-211.
10. Li X, Kimberly RP: Targeting the Fc receptor in autoimmune disease. Expert Opinion on Therapeutic Targets 2014, 18(3):335-350.
11. Morris AB, Pinelli DF, Liu D, Wagener M, Ford ML: Memory T cell-mediated rejection is mitigated by Fc gamma RIIB expression on CD8(+)T cells. American Journal of Transplantation 2020, 20(8):2206-2215.
12. Xia YC, Schuliga M, Shepherd M, Powell M, Harris T, Langenbach SY, Tan PS, Gerthoffer WT, Hogarth PM, Stewart AG et al: Functional Expression of IgG-Fc Receptors in Human Airway Smooth Muscle Cells. American Journal of Respiratory Cell and Molecular Biology 2011, 44(5):665-672.
13. Mousavi SA, Sporstøl M, Fladeby C, Kjeken R, Berg T: Receptor-mediated endocytosis of immune complexes in rat liver sinusoidal endothelial cells is mediated by FcγRIIb2. Hepatology 2007, 46(3):871-884.
14. Ganesan LP, Kim J, Wu Y, Mohanty S, Phillips GS, Birmingham DJ, Robinson JM, Anderson CL: FcγRIIb on liver sinusoidal endothelium clears small immune complexes. The Journal of Immunology 2012, 189(10):4981-4988.
15. Ishikawa T, Yokoyama H, Matsuura T, Fujiwara Y, Wang Y: Fc gamma RIIb expression levels in human liver sinusoidal endothelial cells during progression of non-alcoholic fatty liver disease. PLoS ONE 2019, 14(1).
16. Geraud C, Mogler C, Runge A, Evdokimov K, Lu S, Schledzewski K, Arnold B, Hammerling G, Koch PS, Breuhahn K et al: Endothelial transdifferentiation in hepatocellular carcinoma: loss of Stabilin-2 expression in peri-tumourous liver correlates with increased survival. Liver Int 2013, 33(9):1428-1440.
17. Shevach EM: Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30(5):636-645.
18. Liu H, Shalev I, Manuel J, He W, Leung E, Crookshank J, Liu MF, Diao J, Cattral M, Clark DA et al: The FGL2-Fc gamma RIIB pathway: A novel mechanism leading to immunosuppression. European Journal of Immunology 2008, 38(11):3114-3126.
19. Wenink MH, Santegoets KCM, Roelofs MF, Huijbens R, Koenen HJPM, van Beek R, Joosten I, Meyer-Wentrup F, Mathsson L, Ronnelid J et al: The Inhibitory Fc gamma IIb Receptor Dampens TLR4-Mediated Immune Responses and Is Selectively Up-regulated on Dendritic Cells from Rheumatoid Arthritis Patients with Quiescent Disease. Journal of Immunology 2009, 183(7):4509-4520.
20. Sharma PM, Son HS, Ugi S, Ricketts W, Olefsky JM: Mechanism of SHIP-mediated inhibition of insulin- and platelet-derived growth factor-stimulated mitogen-activated protein kinase activity in 3T3-L1 adipocytes. Molecular endocrinology (Baltimore, Md) 2005, 19(2):421-430.
21. Hoang Van Tong NVB, Nghiem Xuan Hoan3,: Soluble fibrinogen-like protein 2 levels in patients with hepatitis B virus-related liver diseases. BMC Infectious Diseases 2018, 18(553).
22. Jin J, Xu H, Wu R, Gao N, Wu N, Li S, Niu J: Identification of key genes and pathways associated with different immune statuses of hepatitis B virus infection. Journal of Cellular and Molecular Medicine 2019, 23(11):7474-7489.
23. Bertoletti A, Ferrari C: Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Postgrad Med J 2013, 89(1051):294-304.
24. Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts E, Davidson BR, Kennedy PTF, Gill US et al: Circulating and intrahepatic antiviral B cells are defective in hepatitis B. Journal of Clinical Investigation 2018, 128(10):4588-4603.
25. Bjorck P, Beilhack A, Herman EI, Negrin RS, Engleman EG: Plasmacytoid dendritic cells take up opsonized antigen leading to CD4(+) and CD8(+) T cell activation in vivo. Journal of Immunology 2008, 181(6):3811-3817.
26. Sandalova E, Laccabue D, Boni C, Tan AT, Fink K, Ooi EE, Chua R, Shafaeddin Schreve B, Ferrari C, Bertoletti A: Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans. PLoS pathogens 2010, 6(8):e1001051.
27. Das A, Hoare M, Davies N, Lopes AR, Dunn C, Kennedy PT, Alexander G, Finney H, Lawson A, Plunkett FJ et al: Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 2008, 205(9):2111-2124.
28. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G et al: Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. Journal of virology 2007, 81(8):4215-4225.
29. Acerbi G, Montali I, Ferrigno GD, Barili V, Schivazappa S, Alfieri A, Laccabue D, Loglio A, Borghi M, Massari M et al: Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B. J Hepatol 2020.
30. Ma A, Motyka B, Gutfreund K, Shi YE, George R: A dendritic cell receptor-targeted chimeric immunotherapeutic protein (C-HBV) for the treatment of chronic hepatitis B. Human Vaccines & Immunotherapeutics 2020, 16(4):756-778.
31. Li TY, Yang Y, Zhou G, Tu ZK: Immune suppression in chronic hepatitis B infection associated liver disease: A review. World journal of gastroenterology 2019, 25(27):3527-3537.
32. Foerster K, Helmy A, Zhu Y, Khattar R, Adeyi OA, Wong KM, Shalev I, Clark DA, Wong P-Y, Heathcote EJ et al: The novel immunoregulatory molecule FGL2: A potential biomarker for severity of chronic hepatitis C virus infection. Journal of Hepatology 2010, 53(4):608-615.
33. Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S et al: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001, 33(6):1527-1532.
34. Strauss O, Phillips A, Ruggiero K, Bartlett A, Dunbar PR: Immunofluorescence identifies distinct subsets of endothelial cells in the human liver. Sci Rep 2017, 7:44356.
35. Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, Gra-Oramas B, Gonzalez-Fabian L, Lazo-Del Vallin S, Diago M, Adams LA: Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH. Liver international : official journal of the International Association for the Study of the Liver 2017, 37(12):1887-1896.